top of page

Mereo BioPharma’s CEO discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat

  • blonca9
  • Jul 3, 2024
  • 1 min read

Denise Scots-Knight describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the clinical benefit to patients’ lives. Plus, the role that the company’s alvelestat program could play in lung conditions.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page